Immuneering expects cash runway to fund operations into 2029

Immuneering

05/08/2026 12:40

Overview
US oncology drug developer's Q2 net loss beat analyst expectations, loss per share met consensus
Company ended Q2 with $182.7 mln in cash and equivalents, runway anticipated into 2029
Increased R&D expenses driven by clinical costs for atebimetinib program

Outlook
Company expects cash runway to fund operations into 2029
Immuneering plans to begin Phase 2 trial in lung cancer in 2H 2026, with data in late-2027
Topline data from Phase 3 MAPKeeper 301 trial expected in mid-2028

Result Drivers
ATEBIMETINIB CLINICAL COSTS - Increased Q2 R&D expenses primarily driven by clinical costs for atebimetinib program
PHASE 3 TRIAL PROGRESS - Co dosed first patient in pivotal Phase 3 MAPKeeper 301 trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer
FAVORABLE PHASE 2A DATA - Co reported 17.3 month median overall survival and favorable tolerability profile for atebimetinib + mGnP in first-line pancreatic cancer patients

Company press release: ID:nGNXbjwKsK

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
Meet
$0.27
$0.27 (7 Analysts)
Q2 Net Loss
Beat
$17.3 mln
$17.63 mln (6 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Immuneering Corporation is $17.50, about 297.7% above its August 4 closing price of $4.40

Reuters Recommended Reads
Aug 4 - Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand
Aug 4 - Gilead posts smaller-than-expected Q2 loss on sales boost from HIV drugs
Aug 4 - Amgen second-quarter sales rise 9%, profit tops Street view

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)